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Abstract
Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-
cell lymphoma (DLBCL). The aim of this analysis is to report long-term outcome and toxicities in newly diagnosed
DLBCL patients who received R2-CHOP21 in two independent phase 2 trials, conducted by Mayo Clinic (MC) and
Fondazione Italiana Linfomi (FIL). All patients received R-CHOP21 plus lenalidomide. Long-term progression-free
survival (PFS), time to progression (TTP), overall survival (OS) and late toxicities and second tumors were analyzed.
Hundred and twelve patients (63 MC, 49 FIL) were included. Median age was 69 years, 88% were stage III–IV. At a
median follow-up of 5.1 years, 5y-PFS was 63.5%, 5y-TTP 70.1% and 5y-OS 75.4%; according to cell of origin (COO): 5y-
PFS 52.8% vs 64.5%, 5y-TTP 61.6% vs 69.6% and 5y-OS 68.6% vs 74.1% in germinal center (GCB) vs non-GCB
respectively. Four patients experienced grade 4–5 late toxicities. Grade ≤ 3 toxicities were infections (N= 4),
thrombosis (N= 1) and neuropathy (N= 3). Seven seconds tumors were observed. Long-term follow-up demonstrates
that R2-CHOP21 efficacy was maintained with high rates of PFS, TTP, and OS. Lenalidomide appears to mitigate the
negative prognosis of non-GCB phenotype. Incidence of therapy-related secondary malignancies and late toxicities
were low.
Introduction
The addition of the anti-CD20 monoclonal antibody
rituximab, to a chemotherapy regimen with cyclopho-
sphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) dramatically improved the outcome of patients
affected by diffuse large . B-cell lymphoma (DLBCL) and
became the standard of treatment1–4. However, about
40% of patients relapse or do not respond to initial
chemoimmunotherapy, and patients with relapsed
DLBCL have a poor prognosis5,6
Attempts to improve the efficacy of front-line therapy
have included dose-dense and dose-intensified regimens
followed by autologous stem cell transplantation
(ASCT)7–10, the use of different induction schedules11,
early intensification of rituximab administration12, or the
substitution of obinutuzumab for rituximab13. However
they did not improve the outcome of DLBCL patients14.
The biological complexity of DLBCL suggests that a
tailored therapeutic approach based on the biological and
molecular signature might be a promising strategy. Gene-
expression profiling (GEP) identified two major DLBCL
subtypes: the germinal center B-cell like (GCB) and the
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activated B-cell like (ABC) also refered to as GCB and
non-GCB in immunohistochemistry (IHC)-based sub-
typing15,16. DLBCLs with ABC (non-GCB) phenotype are
associated with an unfavorable outcome when treated
with standard R-CHOP 17.
Lenalidomide is an immunomodulatory drug (ImiD)
that demonstrates significant activity in relapsed/refrac-
tory lymphomas in monotherapy and in combination with
rituximab18,19. In xenograft models of DLBCL, lenalido-
mide demonstrated major clinical activity on ABC-sub-
type, in which there was downregulation of B-cell
receptor-dependent NF-kB through an inhibition of the
transcription factor interferon regulatory factor 4 (IRF4)
and cerebron20. Lenalidomide was subsequently investi-
gated as front-line treatment of DLBCL in combination
with standard R-CHOP chemoimmunotherapy adminis-
tered every 21 days (R2-CHOP21). Two phase I/II studies,
conducted by Mayo Clinic (MC078E trial)21,22 and by
Fondazione Italiana Linfomi (FIL, REAL07 trial)23,24
reported that the combination regimen R2-CHOP21 is
feasible and effective, with an overall response rate (ORR)
greater than 90%. These early results have led to two
currently ongoing randomized trials25,26. However, long-
term efficacy and safety of this regimen are not well
defined. Here, we report the results of a combined analysis
on a long-term follow-up of the efficacy and safety in
newly diagnosed DLBCL patients who received R2-
CHOP21 in these two independent single-arm phase
2 studies.
Methods
Study design and participants
This analysis included all patients with newly diagnosed
histologically-confirmed CD20+ DLBCL that were
enrolled in two R2-CHOP21 phase 2 trials; one conducted
by Mayo Clinic (MC078E trial22) between September
2008 and August 2013, and one conducted by Fondazione
Italiana Linfomi (REAL07 trial24) between April 2010 and
June 2011.
MC078E was an investigator-initiated, open-label,
single-arm phase I/II study, while REAL07 was an open-
label, multicentre phase I/II trial that was conducted in 13
centers in Italy and one center in Germany.
Patients in phase II and those from phase I that were
administered the maximum tolerated dose of lenalido-
mide were included in this present long-term analysis.
The main differences between the two populations were
that the MC078E trial included all patients older than 18
years without an upper age limit and all International
Prognostic Index (IPI) risk scores, while the REAL07 trial
focused on patients aged between 60 and 80 years old and
included only patients with IPI score ≥ 2, excluding low
risk IPI score cases. Other inclusion criteria for both
studies were similar and included the following: Ann
Arbor Stage II–IV; measurable disease with at least one
lesion ≥ 1.5 cm in a single diameter by CT; Eastern
Cooperative Oncology Group (ECOG) PS 0–2; estimated
cardiac ejection fraction ≥ 45% (MUGA scan or echo-
cardiogram); and preserved organ functions22,24. Main
exclusion criteria included the following: presence of
central nervous system (CNS) involvement at diagnosis,
HIV, HCV, and HBV infection, history of life-threatening
or recurrent thrombosis and/or embolism, unless they
were receiving anticoagulant therapy during the protocol
treatment; history of any neoplasia in the previous 3 years.
Procedures
All patients included in the analysis received standard
R-CHOP21 treatment in association with lenalidomide
administered in different schemes in the MC078E and
REAL07 trials.
Both studies utilized standard R-CHOP21 therapy
(rituximab 375mg/m2, cyclophosphamide 750mg/m2,
doxorubicin 50mg/m2, vincristine 1.4 mg/m2 (capped at
2 mg), all on day 1, prednisone 100 mg/m2 (MC078E) or
40mg/m2 (FIL-REAL07) per day on days 1 through 5,
given every 21 days).
In the MC078E trial, lenalidomide was administered at a
dose of 25 mg/day for 10 days/cycle (MTD determined in
the phase I trial21), whereas in the REAL07 study, lenali-
domide dose was 15 mg/day for 14 days/cycle (MTD
determined by phase 1 stydy23). Accordingly, the total
cumulative doses of lenalidomide in both studies were
similar: 250 mg/cycle and 210mg/cycle in Mayo Clinic
and FIL study respectively. CNS prophylaxis with 12mg
of intrathecal methotrexate (IT MTX) was administered
in patients with a high risk of CNS progression/relapse
according to local clinical practice. All patients received
primary prophylaxis for neutropenia, with a 6 mg pegfil-
grastim subcutaneous injection on day 2 in MC078E trial
and with granulocyte colony-stimulating factors in
REAL07 trial. Prophylaxis for deep vein thrombosis was as
follows in both trials: low dose aspirin (acetylsalicylic
acid), 81 mg per day and prophylactic low molecular
weight heparins in MC078E and REAL07 trials respec-
tively. Pneumocystis Jirovecii infection prophylaxis with
co-trimoxazole or pentamidine aerosol was administered
according to local clinical practice. Occult carriers of
hepatitis B virus were treated with lamivudine. A pre-
phase treatment with steroids or vincristine in cases of
urgent clinical need was allowed in 7 days before study
treatment. Tumor lysis prophylaxis, antiemetics, and
supportive care were the standard of care and at the
discretion of the treating physician.
Pathology review and DLBCL profile assessment
All histologic diagnoses were confirmed by a central
pathology review using WHO 2008 classification
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diagnostic criteria27 in both trials. COO subtype was
determined by Hans algorithm IHC as either GCB or non-
GCB 15.
In MC078E trial, the histological diagnoses and COO
phenotype were validated independently at the British
Columbia Cancer Agency on a subset of the study cases
(N= 43) for standardization. There was agreement with
the assessment of GCB versus non-GCB in 93% (40 of
43) of cases. As for the REAL07 trial, two pathologists
centrally reviewed diagnostic lymphoma samples
from each patient for IHC COO. Differences of opinion
were resolved by joint review with a multihead
microscope.
Outcome
Progression-free survival (PFS) was defined as the time
from the date of registration until the date of disease
progression or death due to any cause. Time to progres-
sion (TTP) was defined as the time from the date of
registration until the date of disease progression. Overall
survival (OS) was defined as the time from the date of
registration until the date of death as a result of any cause.
Additional analyses of the association between outcome
and cell of origin and IPI were performed.
The incidence of CNS relapses, late toxicities, and sec-
ondary malignancies was reported.
Late toxicities were defined as any type of toxicity that
was reported from the date of the treatment completion
until the date of the last follow-up and recorded as being
possibly, probably or definitely related to study treatment.
Adverse events were defined as per National Cancer
Institute Common Terminology Criteria for Adverse
Events v 4.03. Toxicities were described as maximum
grade occurred for each patient.
Statistical methods
The MC078E trial was a phase II study that utilized a
one-stage binomial design to assess the efficacy and tol-
erability of R2-CHOP21 regimen with 93% power and 9%
type I error rate. The REAL07 trial was a phase II study
designed according to Simon’s two stage minimax design,
with 80% power and 5% type I error rate.
In the present long-term combined analysis from the
two trials, all patients were analyzed as a single cohort.
Long-term outcome results from the two trials separately
were also reported. The distribution of time-to-event
survival end points were estimated by using Kaplan Meier
methods. Differences between groups were evaluated by
log-rank statistics. For PFS and TTP, patients were cen-
sored on the date of their last disease assessment. For OS,
patients were censored on the date of last follow-up. A
subgroup analysis of PFS, TTP, and OS by COO pheno-
type and IPI was performed.
Ethics
The trial was done in accordance with the Declaration
of Helsinki and good clinical practice guidelines. Approval
was obtained from the independent ethics committees
and institutional review boards at each site before trial
initiation. All patients provided written informed consent
to participate in the study.
Results
Between September 2008 and August 2013, 63 patients
with DLBCL were enrolled in the MC078E trial and were
included in the present long-term follow-up analysis. In
the REAL07 phase II trial, 49 patients, enrolled between
October 2008 and June 2011, were included. Hence, the
entire cohort included 112 patients (63 MC078E, 49
REAL07) with de-novo DLBCL.
Clinical characteristics
The median age of the whole cohort was 69 years (range
22–87 years), with 50 (44.6%) patients over age 70 years
and five (4.5%) patients over age 80. Main clinical char-
acteristics are summarized in Table 1.
Patients characteristics included the following: 68
(60.7%) patients; Ann Arbor advanced stage III–IV in 98
(87.5%) cases; B symptoms in 39 (41.1%) cases. According
to IPI, patients were stratified as low/intermediate-low
risk (0–2) in 49 (43.8%) cases and intermediate-high/high
risk (3–5) in 63 (56.3%) cases. According to central ner-
vous system (CNS)-IPI, patients were stratified as low risk
CNS-IPI 0–1 in seven (6.3%), intermediate risk CNS-IPI
2–3 in 82 (73.2%) and high risk CNS IPI 4–6 in 23 (20.6%)
patients. Excluding 22 (19.6%) patients that were not
evaluable for COO IHC testing, GCB vs non-GCB was
observed in 47 (42.0%) vs 43 (38.4%) cases respectively.
Long-term follow-up outcome
MC078E trial and REAL07 trial
At a median FU of 5.1 years (y), 5y-PFS was 59% (95%
CI, 48–73%) vs 69% (95% CI, 57–85%) (p= 0.09), 5y-TTP
was 68% (95% CI, 57–81%) vs 72% (95% CI, 60–88%) (p=
0.24) and 5y-OS was 74% (95% CI, 63–865) vs 77% (95%
CI, 64–92%) (p= 0.28). Since differences in the long-term
outcomes between the two trials were observed to be not
statistically significant, a combined analysis of the two
cohorts was done.
Whole cohort
At a median follow-up of 5.1 years (y), for the whole
cohort, 5y-PFS was 63.5% (95% CI, 54.7–73.6%), 5y-TTP
was 70.1% (95% CI, 61.6–79.9%) and 5y-OS was 75.4% (95%
CI, 67.3–84.5%) (Fig. 1). A total of 32 relapses were
observed, with only 2 cases of CNS relapse. In the two
patients who experienced CNS-relapse, the time from
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randomization to CNS-relapse was 287 and 183 days, the
CNS-IPI was 4 and 3, COO was GCB and non-GCB,
respectively; no intrathecal CNS phrophylaxis was admi-
nistered in these two patients. Late relapse occurring
beyond 3 years was observed in four cases (three cases with
GCB phenotype and one case with missing COO data).
Twenty-five patients died with the following causes:
lymphoma in 15 (60%) patients, late toxicities in one (4%),
second tumors in three (12%), and other causes not
related to hematological disease or treatment in six (24%)
patients (one due to violent cause, one due to diabetes
Table 1 Patient characteristics
MC078E (N= 63) REAL07 (N= 49) Total (N= 112)
Age at diagnosis
N 63 49 112
Mean (SD) 64.5 (13.24) 69.4 (5.16) 66.7 (10.74)
Median 67.0 69.0 69.0
Range 22.0, 87.0 61.0, 79.0 22.0, 87.0
Sex, n (%)
Male 39 (61.9%) 29 (59.2%) 68 (60.7%)
Female 24 (38.1%) 20 (40.8%) 44 (39.3%)
Stage, n (%)
I/II 8 (12.7%) 6 (12.2%) 14 (12.5%)
III/IV 55 (87.3%) 43 (87.8%) 98 (87.5%)
Systemic symptoms, n (%)
A 30 (65.2%) 26 (53.1%) 56 (58.9%)
B 16 (34.8%) 23 (46.9%) 39 (41.1%)
Missing 17 0 17
CNS-IPI, n (%)
1 6 (9.5%) 1 (2.0%) 7 (6.3%)
2 22 (34.9%) 19 (38.8%) 41 (36.6%)
3 25 (39.7%) 16 (32.7%) 41 (36.6%)
4 6 (9.5%) 10 (20.4%) 16 (14.3%)
5 4 (6.3%) 3 (6.1%) 7 (6.3%)
IPI Group, n (%)
0–2 29 (46.0%) 20 (40.8%) 49 (43.8%)
3+ 34 (54.0%) 29 (59.2%) 63 (56.3%)
COO, n (%)
GCB 33 (55.9%) 14 (45.2%) 47 (52.2%)
Non-GCB 26 (44.1%) 17 (54.8%) 43 (47.8%)
Missing 4 18 22
Days from diagnosis to randomization
N 63 49 112
Mean (SD) 16.9 (9.38) 25.5 (14.72) 20.7 (12.71)
Median 14.0 26.0 18.0
Range 4.0, 42.0 1.0, 67.0 1.0, 67.0
IPI International Prognostic Index, CNS-IPI central nervous system-IPI, COO cell of
origin, GCB germinal center B-cell
Fig. 1 Kaplan–Meier curves of progression-free survival, time to
progression, overall survival of the whole cohort
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mellitus type 2 complications, three due to acute cardi-
orespiratory arrest and one due to bacteriemia, all non-
related to lymphoma or treatment according to
investigators).
Outcome results in a subgroup analysis stratifying
patients according to COO were: 5y-PFS was 52.8% (95%
CI, 39.8–70.2%) vs 64.5% (95% CI, 51.1–81.5%) (p=
0.198), 5y-TTP was 61.6% (95% CI, 48.1–78.9%) vs 69.6%
(95% CI, 56.6–85.7%) (p= 0.444) and 5y-OS was 68.6%
(95% CI, 56.1–83.9%) vs 74.1% (95% CI, 61.3–89.7%) (p=
0.238) in GCB vs non-GCB respectively (Fig. 2). Outcome
results in a subgroup analysis stratifying patients accord-
ing to IPI 0–2 vs 3–5 were: 5y-PFS was 69.0% (95% CI,
56.5–84.2%) vs 59.0% (95% CI, 47.5–73.3%) (p= 0.100),
5y-TTP was 73.2% (95% CI, 61.1–87.7%) vs 67.4% (95%
CI, 56.0–81.2%) (p= 0.285) and 5y-OS was 82.3% (95%
CI, 71.7–94.3%) vs 70.2% (95% CI, 59.0–83.5%) (p=
0.059) (Figs. 2 and 3).
Late toxicities and second tumors
Only one toxic death has been recorded in the follow-up
period: a grade 5 sepsis occurred 6 months after the
treatment completion in patient that was not neutropenic.
Three patients experienced a severe grade 4 late toxicity
(all grade 4 persistent neutropenia, subsequently
resolved). Other milder grade ≤ 3 toxicities were: infec-
tions (in four cases, one grade 3 Gram negative bacter-
iemia and three cases of grade 1–2: viral infections in one
case, Gram positive infections in two cases), thrombosis
(one case grade 2) and persistent neuropathy (three cases,
all grade 1–2). Two cases of cardiovascular disease grade 3
were reported.
Second malignancies were observed in seven patients
(6.3%): one (0.9%) case of therapy-related secondary acute
myeloid leukemia; six cases of other not therapy-related
second tumors (two (1.8%) cases of second lymphoma
(one T-cell and one mucosa-associated lymphoid tissue
(MALT) lymphoma), one metastatic adenocarcinoma of
unknown origin, one prostatic cancer, one rectal adeno-
carcinoma, and one non-melanotic tumor of the skin).
Three patients died due to the occurence of the second
tumor. The median time from the end of treatment to the
second neoplasia onset is 16.4 months (range:
5.7–53.3 months).
Discussion
This long-term follow-up analysis demonstrates that in
patients with de novo DLBCL the R2-CHOP21 regimen
maintained high efficacy over time, with high rates of PFS,
TTP, and OS and with a good long-term safety profile.
At a median follow-up of 5.1 years (y), for the whole
cohort, 5y-PFS was 63.5% (95% CI, 54.7–73.6%), 5y-TTP
Fig. 2 Forest plot of progression-free survival, time to
progression and overall survival in a subgroup analysis based on
International Prognostic Index and cell of origin. PFS progression-
free survival, TTP time to progression, OS overall survival, IPI
International Prognostic Index, COO cell of origin, GCB germinal
center B-cell
Fig. 3 Kaplan–Meier curves of overall survival in a subgroup
analysis based on International Prognostic Index and cell of
origin. IPI International Prognostic Index, COO cell of origin, GCB
germinal center B-cell
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was 70.1% (95% CI, 61.6–79.9%) and 5y-OS was 75.4%
(95% CI, 67.3–84.5%) (Fig. 1).
These results find a favorable comparison with histor-
ical data on patients treated with standard R-CHOP.
Nowakowski et al.22, in a control cohort of DLBCL
patients treated with R-CHOP alone, obtained from Mayo
Clinic Database, showed a 2y-PFS of 52%; while in our
present cohort treated with R-CHOP in association to
lenalidomide 5y-PFS in the whole DLBCL cohort was
63.5%. These results are promising on a role of the
addiction of lenalidomide to standard front-line che-
moimmunotherapy in DLBCL setting.
Two randomized studies25,26 have completed accrual
and are expected to be reported in the near future. E1412
is a randomized phase 2 study, which enrolled patients
with newly diagnosed DLBCL regardless of COO and is
powered to analyse COO results separately. Robust trial is
a phase 3 registrational study that enrolled patients with
ABC DLBCL only. These long-term efficacy and safety
data in the present analysis will aid in the interpretation of
the early results of these randomized trials.
In terms of efficacy, the current analysis demonstrates
continuous benefit of R2CHOP with only a few relapses
beyond year 2. Interestingly, late relapses appeared to
occur in the GCB subtype.
In a subgroup analysis by the clinical prognostic index
IPI, we can observe that IPI remained almost significantly
predictive of survival (with patients with IPI score >
3 showing inferior OS, p= 0.059).
However, if we compared the outcome results of
patients with intermediate-high/high IPI risk treated with
R2-CHOP in our cohort, to historical data of IPI > 3
DLBCL treated with R-CHOP standard, we observed a 3y-
OS of 80.5% vs 65.1% (IPI 3) and 59.0% (IPI 4–5) in
patients treated with R2-CHOP vs historical R-CHOP
treated control cohort, respectively28. These data sug-
gested a role of association of lenalidomide to standard R-
CHOP in improving the prognosis also of intermediate-
high/high risk patients.
Both MC078E and REAL07 trials performed an
exploratory analysis of patients treated with the combi-
nation regimen R2-CHOP21 in GCB vs non-GCB phe-
notype, suggesting that the addition of lenalidomide could
mitigate the negative prognostic impact of the non-GCB
subtype22,24. In the MC078E study22, a cohort of con-
secutive DLBCL patients, stage II–IV, from the Mayo
Clinic Lymphoma Database treated with standard R-
CHOP21 was retrospectively analyzed as a control. The
outcome of the non-GCB phenotype was inferior to that
of GCB in DLBCL patients treated with R-CHOP21 alone
(2y-PFS in non-GCB vs GCB subtype of 28% vs 64%,
respectively, p= 0.001), while there was no difference in
outcome between the non-GCB vs GCB subtype in
patients treated with R2-CHOP21 combination regimen.
The current analysis demonstrates a durable benefit of
R2-CHOP in non-GCB DLBCL, while results on GCB
DLBCL showed to be superimposable to what obtained
with standard R-CHOP22. This long-term response seems
to translate into an apparent survival benefit in non-GCB
DLBCL when compared to historical controls (2y-OS in
R-CHOP treated cohort was 46% vs 5y-OS of 74.1%
reported in our cohort of non-GCB DLBCL patients
treated with R2-CHOP). Moreover, R2-CHOP21 was
effective in patients with a high-intermediate/high IPI
score and an older age (44.6% and 4.5% were over 70 and
80 years old, respectively).
A more accurate definition of COO, if compared with
IHC, could be provided by GEP analysis such as the
Nanostring® platform. In order to better evaluate the role
of the association of lenalidomide to standard che-
moimmunotherapy in different COO phenotypes, Nano-
string® analysis in these patients is ongoing. Other recent
trials to improve front-line outcomes of DLBCL patients
investigated new regimens in both GCB and non-GCB/
ABC subtypes. In the recent published GOYA trial13,
which included more patients with a low-intermediate IPI
risk score compared to the population of our study, a
subgroup analysis according to COO determined by GEP
was performed. A 3y-PFS of 75%, 59%, and 63% for the
GCB, ABC, and unclassified phenotype, respectively, was
reported with no difference between the rituximab and
obinotuzumab arms. When compared to the 3y-PFS of
patients treated with R2-CHOP in our analysis, the
combination of lenalidomide may influence outcomes in
non-GCB subtype DLBCL (3y-PFS of 61.2% and 67.4% in
GCB and non-GCB respectively). The role of the combi-
nation of lenalidomide with standard R-CHOP21 in other
subgroups of DLBCL with worse prognosis, such as MYC/
BCL2 double expressors or double hit lymphomas
remains to be defined, and further studies are ongoing.
Future directions on the optimal use of lenalidomide
toward a tailored therapy in DLBCL patients could come
from the most recent advances in genetic and molecular
knowledge of DLBCL29.
Despite a large number of intermediate/high CNS-IPI
patients, CNS recurrences were less than expected, sug-
gesting a role of lenalidomide combination in decreasing
the risk of CNS involvement. There is evidence that small
molecules, such as lenalidomide, could cross the
blood–brain barrier. Lenalidomide also has been
demonstrated to have single-agent activity in primary
CNS lymphomas. In addition, non-GCB/ABC DLBCL are
more likely to involve the CNS, and improved outcomes
in this subgroup of patients could contribute to a reduced
CNS-relapse rate30.
The addition of a new drug to standard chemoimmu-
notherapy raises concerns of increased toxicities, espe-
cially in older patients. This long-term follow-up analysis
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demonstrates that no new worrisome safety signals were
observed in patients treated with an R2-CHOP21 com-
bination regimen. In 112 patients, only one toxic death
has been recorded in the follow-up period, a grade
5 sepsis that occurred 6 months after the completition of
treatment. The other grade 4 late toxicities were grade 4
persistent neutropenia and all subsequently resolved.
Among the four cases of infections reported, only two
cases occurred in neutropenic patients (the case of grade 3
Gram negative bacteriemia and one grade 1–2 infection),
and both resolved. The only patient death secondary to
sepsis was not related to neutropenia at the time of the
event. In keeping with earlier published results which
suggested that the incidence of neuropathy was low21–24
with R2CHOP21, long-term analysis shows only three
patients reported a persistent neuropathy, all mild/grade
1–2. Two cases of cardiovascular disease grade 3 were
observed, but it must be noted that the median age of
patients was high and cardiotoxicity could be attributed
mainly to antracycline-based therapy.
The incidence of second malignancies was comparable
rates in patients treated with RCHOP31. Moser et al.,
reported, for patients treated with CHOP or CHOP like
therapy, a cumulative incidence at 15 years of therapy-
related secondary acute leukemia/myelodysplastic syn-
drome and other tumors of 3% and 11% respectively30. In
our cohort, the cumulative incidence at 5 years was 0.9%
and 5.4% respectively. Indeed, considering the median age
of patients, prostatic cancer and tumor of the skin are
quite common in this population.
In conclusion, our long-term follow-up combined ana-
lysis from two phase II trials shows that R2-CHOP21
efficacy was maintained over time with a high rate of PFS,
TTP, and OS, considering high risk feature patients that
were included. The addition of lenalidomide to RCHOP
appears to mitigate the negative prognostic impact of
non-GCB phenotype. The incidence of therapy related
secondary malignancies was low, and no new worrisome
long-term safety concerns were reported. Phase III ran-
domized trials have recently concluded, with early results
expected in the near future. These long-term efficacy and
safety data will aid in the interpretation of the results.
Acknowledgements
Celgene provided funding for the two phase 2 studies from which the data
were obtained. Celgene had no role in study design, data collection, data
analysis, data interpretation, or manuscript preparation. Fondazione Italiana
Linfomi.
Author contributions
A.C., A.C., T.E.W., U.V., and G.S.N.: Study design, data collection, data
interpretation, manuscript writing and editing. G.C., B.R.L, L.D.P.: data analysis,
data interpretation, Figures, Tables, manuscript writing and editing. G.G., W.R.
M., G.I., C.B.R., A.T., R.L.K., A.C., J.M.F., V.P., C.E.R., M.S., S.M.A., F.C., A.L.M., T.M.H.:
data collection, data interpretation, manuscript editing.
Author details
1Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino,
Torino, Italy. 2Mayo Clinic, Rochester, MN, USA. 3Department of translational
Medicine, University of Eastern Piedmont, Novara, Italy. 4Cornell University,
New York, NY, USA. 5Mayo Clinic, Scottsdale, AZ, USA. 6Azienda Ospedaliera
Spedali Civili di Brescia, Brescia, Italy. 7IRCCS Azienda Ospedaliera Universitaria
San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
8Mayo Clinic, Jacksonville, FL, USA. 9Unit of Hematology and Hemopoietic
Stem Cell Transplantation, Ospedale Cardinale G Panico, Tricase, Italy.
10Division of Medical Oncology, Centro di Riferimento Oncologico Aviano
National Cancer Institute, Aviano, Italy. 11Department of Oncology and
Hematology, Infermi Hospital, Rimini, Italy. 12Unit of Clinical Epidemiology,
CPO, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di
Torino, Torino, Italy
Conflict of interest
A.Ch.: advisory board: Celgene, Janssen; honoraria for lectures: Amgen,
Celgene, Janssen, Nanostring, Roche, Teva. G.G.: consultancy: Roche,
Karyopharm, Morphosys, Gilead, Janssen, Novartis; honoraria: Roche,
Karyopharm, Morphosys, Gilead, Janssen, Novartis; speakers bureau: Roche,
Gilead, Janssen, Novartis. J.M.F.: Celgene grants during the study conductions.
F.C.: honoraria: Celgene, Onyx, Janssen. T.E.W.: honoraria from Celgene,
personal fees from Seattle genetics, outside the submitted work. U.V.: advisory
board: Roche, Celgene, Janssen; honoraria for lectures: Roche, Celgene, Takeda,
Gilead, Janssen, Mundipharma; research funding: Roche, Celgene. G.N.:
consultancy: Bayer; research funding: Bayer, Celgene, Morphosys, Nanostring
tecnologies. The remaining authors declare that they have no conflict of
interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 28 June 2018 Revised: 12 September 2018 Accepted: 25
September 2018
References
1. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHO-
Palone in elderly patients with diffuse large-B-cell lymphoma. New Engl. J. Med.
346, 235–242 (2002).
2. Habermann, T. M. et al. Rituximab-CHOP versus CHOP alone or with main-
tenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin.
Oncol. 24, 3121–3127 (2006).
3. Pfreundschuh, M. et al. CHOP-like chemotherapy plus rituximab versus CHOP-
like chemotherapy in young patients with good-prognosis diffuse large B-cell
lymphoma: a randomized controlled trial by the MabThera International Trial
(MInT) Group. Lancet Oncol. 7, 379–391 (2006).
4. Sehn, L. H. et al. Introduction of combined CHOP plus rituximab therapy
dramatically improved outcome of diffuse large B-cell lymphoma in British
Columbia. J. Clin. Oncol. 23, 5027–5033 (2005).
5. Farooq, U. et al. Clinical heterogeneity of diffuse large B-cell lymphoma fol-
lowing failure of front-line immunochemotherapy. Br. J. Haematol. 179, 50–60
(2017).
6. Maurer, M. J. et al. Event-free survival at 24 months is a robust end point for
disease-related outcome in diffuse large B-cell lymphoma treated with
immunochemotherapy. J. Clin. Oncol. 32, 1066–1073 (2014).
7. Delarue, R. et al. R-CHOP14 compared to R-CHOP21 in elderly patients with
diffuse large B cell lymphoma: results of the interim analysis of the LNH03-6B
GELA study. Blood 114, 169 (2009). [abstract 406].
8. Chiappella, A. et al. Rituximab-dose-dense chemotherapy with or without
high-dose chemotherapy plus autologous stem-cell transplantation in high-
risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre,
open-label, randomised, controlled, phase 3 study. Lancet Oncol. 18,
1078–1088 (2017).
9. Schmitz, N. et al. German High-Grade Lymphoma Study Group (DSHNHL).
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose
Castellino et al. Blood Cancer Journal           (2018) 8:108 Page 7 of 8
Blood Cancer Journal
chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with
aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial
(DSHNHL 2002-1). Lancet Oncol. 13, 1250–1259 (2012).
10. Stiff, P. J. et al. Autologous transplantation as consolidation for aggressive non-
Hodgkin’s lymphoma. N. Engl. J. Med. 369, 1681–1690 (2013).
11. Dholaria, B. et al. DA.R-EPOCH vs. R-CHOP for high-risk diffuse large B- cell
lymphoma: The Mayo Clinic Florida Experience. Blood 130, 1572 (2017).
12. Lugtenburg, P. J. et al. Randomized phase III study on the effect of early
intensification of rituximab in combination with 2-weekly CHOP chemother-
apy followed by rituximab or no maintenance in patients with diffuse large B-
cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.
JCO.2016.34.15_suppl.7504.
13. Vitolo, U. et al. Obinutuzumab or rituximab plus cyclophosphamide, doxor-
ubicin, vincristine, and prednisone in previously untreated diffuse large B-cell
lymphoma. J. Clin. Oncol. 35, 3529–3537 (2017).
14. Alizadeh, A. A. et al. Prediction of survival in diffuse large B-cell lymphoma
based on the expression of 2 genes reflecting tumor and microenvironment.
Blood 118, 1350–1358 (2011).
15. Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B-
cell lymphoma by immunohistochemistry using a tissue microarray. Blood
103, 275–282 (2004).
16. Choi, W. W. et al. A new immunostain algorithm classifies diffuse large B-cell
lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 15,
5494–5502 (2009).
17. Rosenwald, A. et al. The use of molecular profiling to predict survival after
chemotherapy for diffuse large B-cell lymphoma. N. Engl. J. Med. 346,
1937–1947 (2002).
18. Czuczman, M. S. et al. A phase 2/3 multicenter, randomized study comparing
the efficacy and safety of lenalidomide versus investigator’s choice in
relapsed/refractory DLBCL. Clin. Cancer Res. 16, 2818 (2017).
19. Hernandez-Ilizaliturri, F. J. et al. Higher response to lenalidomide in relapsed/
refractory diff use large B-cell lymphoma in nongerminal center B-cell-like than
in germinal center B-cell-like phenotype. Cancer 117, 5058–5066 (2011).
20. Zhang, L. H. et al. Lenalidomide efficacy in activated b-cell-like subtype diffuse
large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br. J.
Haematol. 160, 487–502 (2013).
21. Nowakowski, G. S. et al. Lenalidomide can be safely combined with R-CHOP
(R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I
study. Leukemia 25, 1877–1881 (2011).
22. Nowakowski, G. S. et al. Lenalidomide combined with R-CHOP overcomes
negative prognostic impact of non–germinal center B-cell phenotype in
newly diagnosed diffuse large B-Cell lymphoma: A Phase II Study. J. Clin. Oncol.
33, 251–257 (2014).
23. Chiappella, A. et al. Lenalidomide plus cyclophosphamide, doxorubicin, vin-
cristine, prednisone and rituximab is safe and eff ective in untreated, elderly
patients with diff use large B-cell lymphoma: phase I study by the Fondazione
Italiana Linfomi. Haematologica 98, 1732–1738 (2013).
24. Vitolo, U. et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated
diff use large B-cell lymphoma: results of the REAL07 open-label, multicentre,
phase 2 trial. Lancet Oncol. 15, 730–737 (2014).
25. Nowakowski, G. S. et al. ROBUST: lenalidomide-R-CHOP versus placebo-R-
CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future
Oncol. 12, 1553–1563 (2016). (ClinicalTrial.gov Identifier NCT02285062).
26. King, R. L. et al. Rapid, real time pathology review for ECOG/ACRIN 1412: a
novel and successful paradigm for future lymphoma clinical trials in the
precision medicine era. Blood Cancer J. 8, 27 (2018) (ClinicalTrial.gov Identifier
NCT01856192).
27. Campo, E. et al. The 2008 WHO classification of lymphoid neoplasms and
beyond evolving concepts and practical applications. Prepublished Online 117,
5019–5032 (2011).
28. Ziepert, M. et al. Standard International prognostic index remains a valid
predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in
the rituximab era. J. Clin. Oncol. 29, 779 (2011).
29. Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma.
NEJM 378, 1396–1407 (2018).
30. Ayed, A. O. et al. CNS relapse in patients with DLBCL treated with lenalido-
mide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. Blood Cancer
J. 8, 63 (2018).
31. Moser, E. C. et al. Risk of second cancer after treatment of aggressive non-
Hodgkin’s lymphoma; an EORTC cohort study. Haematologica 91, 1481–1488
(2006).
Castellino et al. Blood Cancer Journal           (2018) 8:108 Page 8 of 8
Blood Cancer Journal
